{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antidiabetic+background+therapy", "query": { "intervention": "Antidiabetic background therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T23:41:58.176Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03713684", "title": "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Efpeglenatide SAR439977", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 370, "start_date": "2018-11-09", "completion_date": "2021-01-04", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03713684" }, { "nct_id": "NCT03434119", "title": "Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/Lixisenatide", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2018-02-20", "completion_date": "2019-01-07", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 85, "location_summary": "Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434119" }, { "nct_id": "NCT02320721", "title": "Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Glargine (HOE901 - U300)", "type": "DRUG" }, { "name": "Insulin Glargine (HOE901 - U100)", "type": "DRUG" }, { "name": "Background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1014, "start_date": "2015-01", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 64, "location_summary": "Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more", "locations": [ { "city": "Saraland", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02320721" }, { "nct_id": "NCT03640221", "title": "Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Hydrochlorothiazide 12.5mg", "type": "DRUG" }, { "name": "Microneurography", "type": "DEVICE" }, { "name": "SKNA recordings", "type": "OTHER" }, { "name": "Static Handgrip", "type": "OTHER" }, { "name": "Post-handgrip forearm vascular occlusion", "type": "OTHER" }, { "name": "Testing of the Arterial Baroreflex Function", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "35 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2018-09-01", "completion_date": "2020-08-31", "has_results": false, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03640221" }, { "nct_id": "NCT02856113", "title": "Phase 3 Alogliptin Pediatric Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Alogliptin Benzoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 152, "start_date": "2016-10-14", "completion_date": "2022-02-14", "has_results": true, "last_update_posted_date": "2022-10-19", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 34, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palmdale", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02856113" }, { "nct_id": "NCT02738151", "title": "Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine, 300U/mL", "type": "DRUG" }, { "name": "Insulin degludec, 100 U/mL", "type": "DRUG" }, { "name": "Non-insulin anti-diabetic treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 929, "start_date": "2016-05-19", "completion_date": "2017-08-15", "has_results": true, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 74, "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Chino", "state": "California" }, { "city": "Huntington Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02738151" }, { "nct_id": "NCT02060383", "title": "Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cushing's Disease", "Acromegaly" ], "interventions": [ { "name": "Pasireotide s.c.", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Pasireotide LAR", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2014-05-23", "completion_date": "2018-03-26", "has_results": true, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 15, "location_summary": "Multiple Locations, California • Torrance, California • Ventura, California + 10 more", "locations": [ { "city": "Multiple Locations", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060383" }, { "nct_id": "NCT01798706", "title": "Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antidiabetic background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 350, "start_date": "2013-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 14, "location_summary": "La Jolla, California • Norwalk, California • Miami, Florida + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Norwalk", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798706" }, { "nct_id": "NCT03285594", "title": "Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Sotagliflozin", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Oral Antidiabetes Drugs (OADs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 571, "start_date": "2017-09-15", "completion_date": "2019-09-27", "has_results": true, "last_update_posted_date": "2021-05-11", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 50, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Lincoln", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03285594" }, { "nct_id": "NCT02787551", "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin glargine/lixisenatide fixed ratio combination", "type": "DRUG" }, { "name": "liraglutide", "type": "DRUG" }, { "name": "exenatide", "type": "DRUG" }, { "name": "exenatide extended-release", "type": "DRUG" }, { "name": "albiglutide", "type": "DRUG" }, { "name": "dulaglutide", "type": "DRUG" }, { "name": "Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 514, "start_date": "2016-07-06", "completion_date": "2018-11-17", "has_results": true, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-09-03T23:41:58.176Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02787551" } ] }